Table 5 Comparison of axial elongation among patients achieving treatment goals with 0.025% Atropine + Orthokeratology, Orthokeratology Alone, 0.01%Atropine + Orthokeratology, and 0.025% Atropine + Orthokeratology.

From: Efficacy and safety of orthokeratology sequentially combined with escalating atropine concentrations for myopia control in children

 

OK (n = 64)

OK + 0.01%ATP

OK + 0.025%ATP

F

P

(n = 64)

(n = 64)

Axial elongation(mm)/6 m

0.20 ± 0.08*#

0.15 ± 0.10*&

0.07 ± 0.08#&

36

< 0.001

Axial elongation(mm)/12 m

0.44 ± 0.11*#

0.33 ± 0.11*&

0.16 ± 0.10#&

110.76

< 0.001

  1. Axial elongation(mm),6 m, 6-month; 12 m,12-month; OK, orthokeratology lens; OK + 0.01%ATP, orthokeratology lens combined with 0.01% atropine eye drops; OK + 0.025%ATP, orthokeratology lens combined with 0.025% atropine eye drops, *Representatives of the OK group and OK + 0.01% ATP show a statistically significant difference, # Representatives of the OK group and OK + 0.025% ATP show a statistically significant difference, & Representative OK + 0.01% ATP and OK + 0.025% ATP have statistical differences.
Back to article page